Eli Lilly And Co presently has a consensus rating of "Hold" and a consensus target price of $104.25. Finally, SunTrust Banks reaffirmed a "buy" rating and set a $105.00 price target on shares of Eli Lilly And Co in a research report on Tuesday, July 31st. Credit Suisse Group boosted their target price on Eli Lilly And Co from $84.00 to $86.00 and gave the stock an "underperform" rating in a research note on Wednesday, July 25th. Also, SVP Alfonso G. Zulueta sold 6,000 shares of the business's stock in a transaction dated Tuesday, September 18th. Marathon Oil Corporation (NYSE:MRO) declined to -1.13% closing at the price of $23.72 whereas the shares of Eli Lilly and Company (NYSE:LLY) soared 4.02% with the increase of 4.37 points closing at the price of $112.99. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company. The stock was sold at an average price of $14.58, for a total value of $100,091.70. Analysts consider this stock active, since it switched over with 10,940,820 shares as compared to its average volume of 3.75M shares. In addition, the firm has debt to equity ratio of 1.06, sometimes it remain same with long term debt to equity ratio. Eli Lilly And Co has a 12-month low of $73.69 and a 12-month high of $115.68.
Eli Lilly and Company (NYSE:LLY)'s EPS was $1.5 as reported for the June quarter. The firm had revenue of $6.36 billion for the quarter, compared to analyst estimates of $6.05 billion. Eli Lilly and Company's institutional ownership is 79.2%, while its institutional transactions stand at -0.22%. Eli Lilly And Co's revenue was up 9.1% on a year-over-year basis. The 52-week high of the stock is now $236.62 while its 52-weeks low stands at $198.85. The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. It is a positive indicator for investor portfolio value - when the price of a stock Investor owns goes up in value. Moreover, Fred Alger Mngmt has 0.01% invested in Eli Lilly and Company (NYSE:LLY) for 32,001 shares. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The volume of the company in the last trading session was 6.2 Million. The stock was sold at an average price of $106.31, for a total transaction of $637,860.00. Following the completion of the sale, the senior vice president now owns 55,224 shares of the company's stock, valued at approximately $5,870,863.44. The disclosure for this sale can be found here. It has a total of 1.07 billion million outstanding shares, with an ATR of around 1.77. Loomis Sayles Ltd Partnership invested 0.06% in Eli Lilly and Company (NYSE:LLY). The analysts projected EPS of $1.3/share depicting a Surprise of 15.4 Percent.
TransEnterix, Inc. (NYSE:TRXC) shares depreciated -6.74% over the last trading period, taking overall 5-day performance up to -3.81%. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in shares of Eli Lilly And Co in the 2nd quarter worth approximately $114,000.
Using this figure, stock traders in the market are able to analyze that whether not a stock is making progress and covering both buying side as well as selling side. Morgan Stanley increased its stake in Eli Lilly And Co by 37.8% in the 2nd quarter. During the same period in the previous year, the firm earned $1.11 earnings per share. The stock price soared 29.29% in three months and jumped 47.03% for the last six months trading period. Financial Management Professionals Inc. purchased a new stake in Eli Lilly And Co during the 2nd quarter valued at $128,000.
For personal guess ROI is usually expressed as a percentage and is typically used for taking any financial decisions, for the objective of comparing a Eli Lilly and Company (NYSE:LLY)'s profitability or to compare the efficiency of different investments, hence, LLY return on investment (ROI) is 6.60%. Institutional investors and hedge funds own 76.56% of the company's stock.
Eli Lilly and Company (NYSE:LLY) of the Pharmaceuticals & Biotechnology sector closed the recent session at 108.620000 with a market value of $108348743. It operates through two divisions, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: What is a Call Option?